In light of this, we posit that PARP inhibitor, olaparib, which is conventionally used as maintenance treatment for cancer patients who have deleterious germline BRCA1/2 mutations, may be used to treat metastatic PanNET patients with somatic BRCA1/2 mutations. The gene discussed is BRCA1; the disease is cancer.